Evaluation of characteristics and outcomes of head and neck squamous cell carcinoma in post-transplant patients.
TL;DR
In a cohort of 5,815 transplant patients, most cases of post-transplant HNSCC were localized cSCC managed with surgery alone, reinforcing the value of annual skin exam screenings in SOTRs.
Abstract
669 Background: While it is well established that solid organ transplant recipients (SOTRs) are at increased risk for post-transplant related malignancy, there is a paucity of literature examining the outcomes of patients who develop post-transplant head and neck squamous cell carcinoma (HNSCC) with limited studies showing SOTRs presenting with more aggressive patterns of HNSCC, higher risk of disease recurrence, and decreased survival. Multiple society guidelines recommend an annual skin exam to screen for cutaneous cancers. However, there is no strong recommendation for screening of HNSCC. The goal of our study was to examine clinical trajectories in those who develop post-transplant HNSCC, to help inform screening practices, prognostic counseling, and treatment strategies. Methods: We performed a single institution retrospective study to investigate characteristics and outcomes in SOTRs who develop HNSCC. We identified patients who developed HNSCC after solid organ transplant treated at the University of Chicago Medical Center from 2010-2025 using automated tools in the electronic medical record. Results: Out of a cohort of 5,815 transplant patients, we identified 105 SOTRs who developed cancer in the head and neck region. Of these patients, 67 (63.8%) had cutaneous SCC (cSCC) requiring surgery alone. 38 (36.2%) developed HNSCC requiring systemic therapy and were included in our analysis. 29.0% were heart transplant recipients, 34.2% kidney, 13.2% liver, 7.9% lung, and 15.8% multi-organ. The mean time from transplant to diagnosis of HNSCC was 11 years (SD 9.4, median 8, range 4 months-34 years). 42.1% of patients reported light to heavy tobacco use. 18.4% of tumors were HPV-positive. The primary site of cancer was 50% cutaneous, 18.4% oral cavity, and 31.6% oropharynx. 10.5% of patients had distant disease at the time of diagnosis. For initial treatment, 26.3% received chemoradiation, 55.3% received surgery with neoadjuvant and/or adjuvant treatment, and 18.4% received systemic treatment alone. 47.4% had a documented recurrence after initial treatment (78% local recurrence and 22% distant recurrence). The mean time to recurrence was 1.74 years (SD 3.0, median 0.96). Conclusions: In our cohort, most cases of post-transplant HNSCC were localized cSCC managed with surgery alone, reinforcing the value of annual skin exam screenings in SOTRs. Although the incidence of HNSCC requiring systemic therapy was overall infrequent, SOTRs can develop HNSCC many years after transplant. Despite aggressive treatment, those who develop HNSCC face a substantial risk of recurrent disease, emphasizing the need for long-term surveillance after transplantation and close follow-up after cancer treatment. Given that a significant proportion of patients were tobacco users, patient education on the risk of HNSCC and symptom recognition for early disease detection may be of value in high-risk SOTRs.